Biocon Appoints Shreehas Tambe as CEO & MD

Biocon has announced a key leadership transition, appointing Shreehas Pradeep Tambe as its Chief Executive Officer and Managing Director, effective April 1, 2026. He succeeds Siddharth Mittal, who will move on from the role after a long tenure with the company.

The leadership change comes at a strategically important phase for Biocon, as it consolidates its biologics and generics businesses into a single integrated global platform. This move is aimed at enhancing scale, improving operational efficiency, and strengthening the company’s competitive position across international markets.

Tambe brings nearly three decades of experience within the Biocon ecosystem, having grown through the ranks since joining early in his career. Most recently, he led Biocon Biologics, where he played a crucial role in expanding the company’s footprint in the global biosimilars space and executing key acquisitions and integrations.

His elevation reflects continuity in leadership, particularly given his involvement in major strategic initiatives, including scaling global operations and building integrated manufacturing capabilities. As CEO, Tambe is expected to focus on streamlining operations, driving synergies, and accelerating sustainable growth across the unified organisation.

The transition also marks a broader leadership realignment, with the company strengthening its senior management team to support its integrated structure. This includes renewed focus on financial discipline, operational execution, and global market expansion.

Outgoing CEO Siddharth Mittal has been instrumental in shaping Biocon’s growth journey over the past decade, contributing to its evolution into a global biopharma player. His next role within the broader Biocon Group is expected to leverage his experience in driving strategic initiatives.

With this transition, Biocon is entering a phase where the emphasis shifts from expansion to integration and execution. The success of this model will depend on how effectively the company leverages its combined capabilities across biologics and generics while navigating a competitive and highly regulated global pharmaceutical landscape.

As global demand for affordable and complex therapies continues to rise, Biocon’s integrated approach is expected to play a key role in defining its next growth chapter.